Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has undergone rapid changes with innovations in oncogene-directed therapy and immune checkpoint inhibitors. In patients with epidermal growth factor receptor (EGFR) gene mutant (EGFRm) NSCLC, newer-generation tyrosine...

Full description

Bibliographic Details
Main Authors: Nathaniel Wiest, Umair Majeed, Karan Seegobin, Yujie Zhao, Yanyan Lou, Rami Manochakian
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
Non-small cell lung cancer
lung cancer
EGFR
tyrosine kinase inhibitor
immune-mediated adverse effects
immune checkpoint inhibitor (ICI)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.751209/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.751209/full

Similar Items